Juvenescence

Juvenescence is a pioneering, clinical-stage biopharmaceutical company with a singular mission: to extend the healthy human lifespan by developing therapeutics that target the fundamental biology of aging. The company leverages a world-class R&D team with extensive drug development experience and employs AI-enabled platforms to accelerate and de-risk its pipeline. With a goal of having five medicines in Phase I or II trials by 2025, Juvenescence is positioning itself at the forefront of the rapidly emerging longevity therapeutics market, aiming to transform aging from a period of chronic disease to one of sustained health.

AI-enabled drug discovery and development platform focusing on targets within core aging pathways, utilizing adaptive clinical trial designs with biomarker stratification.

Juvenescence operates in the competitive and fast-evolving longevity biotech sector, competing with companies like Unity Biotechnology (senolytics), Calico (Google-backed), Altos Labs, and Life Biosciences. Its key differentiators are its focus on a diversified pipeline targeting multiple aging mechanisms, its experienced drug development leadership with a commercial track record, and its integration of AI/ML tools to accelerate R&D.